Kashiv BioSciences Partners with Amneal Pharmaceuticals to Commercialize ADL018 (Biosimilar, Xolair)
Shots:
- Kashiv BioSciences has signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018, a biosimilar version of Xolair (omalizumab), across the US. ADL018 is being investigated under the P-III clinical trial initiated during Q3’23
- ADL018 is intended for the treatment of all the indications of omalizumab incl. severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergies, & chronic spontaneous urticaria
- Furthermore, the financial terms of the agreement are undisclosed with any incremental expenses linked to these products considered within Amneal’s guidance
Ref: Businesswire | Image: Kashiv
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
